A dynamic and collaborative health care ecosystem is crucial to conducting efficient and effective clinical trials, but two-thirds of trials fail to enroll enough participants. Misconceptions and a lack of awareness about this important research often keep people from participating. That’s why we recognized Clinical Trials Awareness Week – to shine a spotlight on the unsung heroes of clinical trials, including patients and researchers, like Nina and Abbe, who each shared their take on the clinical trial process with us.
Last Thursday, PhRMA joined hundreds of organizations and individuals during this observance to thank these heroes and raise awareness about the critical need for increased participation in clinical trials. A wealth of insights and unique perspectives were shared, demonstrating the importance of involving all stakeholders to educate and empower people to learn more about whether participation in a clinical trial is right for them. From demystifying the process to providing tools to help locate a trial, physicians, researchers, clinical trial participants, advocacy groups and many others raised awareness about clinical trial participation.
Special thanks to our panelists for sharing their insights with us:
- Nina Martinez, clinical trial participant
- Mohamed E. Salem, MD, Georgetown University Lombardi Comprehensive Cancer Center
- Michael J. Fox Foundation
- Coalition for Clinical Trials Awareness
- Eli Lilly and Company
America’s biopharmaceutical research companies are committed to increasing awareness about clinical trials. See what they had to say during our Clinical Trials Awareness Week.
During Clinical Trial Awareness Week, May 2-6, we’re applauding the individuals who have made innovative medicines a reality. #CTAW2016— Bristol-Myers Squibb (@bmsnews) May 2, 2016
While Clinical Trials Awareness Week may be over, the need to spread the word about the importance of clinical trials never fades. Get the facts about how America's biopharmaceutical companies are designing new ways to conduct clinical trials to increase efficiency and bring medicines to patients faster. Learn more here.
Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Topics: Clinical Trials